I wasn't at all troubled by what the panel had to say. Who cares? What I found interesting was the emphasis the CEO placed on IP and the warning that any other companies are going to struggle using adult stem cells without infringing on one of the MSB patents. Also the valuation methodology based on 50% success probability for Phase III was interesting. I checked this out and, in a 2013 study, 55% of Phase III projects file for approval and 80% of these receive it so with four Phase III trials the odds are bloody good. I'll be upping my investment this week. Like Pixie I initially bought in under $3.00 but I think that was far riskier than buying for $6 or so now.
I wasn't at all troubled by what the panel had to say. Who...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |